Stock ENTX ENTERA BIO LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Entera Bio Ltd.

Equities

ENTX

IL0011429839

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.98 USD -1.00% Intraday chart for Entera Bio Ltd. -0.50% +230.00%
Apr. 08 Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research CI
Mar. 26 Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
AQ
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research
CI
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
AQ
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months
CI
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
CI
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
AQ
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Top Premarket Gainers
MT
Top Premarket Gainers
MT
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
AQ
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
AQ
Entera Bio Ltd. announced that it has received $6.610594 million in funding
CI
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding
CI
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
AQ
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform
CI
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENTX Stock
  4. News Entera Bio Ltd.